These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

257 related items for PubMed ID: 35124267

  • 21. Alpha-fetoprotein, protein induced by vitamin K absence or antagonist-II, lens culinaris agglutinin-reactive fraction of alpha-fetoprotein alone and in combination for early detection of hepatocellular carcinoma from nonalcoholic fatty liver disease: A multicenter analysis.
    Guan MC, Ouyang W, Liu SY, Sun LY, Chen WY, Tong XM, Zhu H, Yang T.
    Hepatobiliary Pancreat Dis Int; 2022 Dec; 21(6):559-568. PubMed ID: 35643910
    [Abstract] [Full Text] [Related]

  • 22. Validation of a Novel Multitarget Blood Test Shows High Sensitivity to Detect Early Stage Hepatocellular Carcinoma.
    Chalasani NP, Porter K, Bhattacharya A, Book AJ, Neis BM, Xiong KM, Ramasubramanian TS, Edwards DK, Chen I, Johnson S, Roberts LR, Kisiel JB, Reddy KR, Singal AG, Olson MC, Bruinsma JJ.
    Clin Gastroenterol Hepatol; 2022 Jan; 20(1):173-182.e7. PubMed ID: 34391922
    [Abstract] [Full Text] [Related]

  • 23. GALAD score as a prognostic model for recurrence of hepatocellular carcinoma after local ablation.
    Qiao W, Li J, Xiong Y, Zheng J, Jin R, Hu C.
    J Cancer Res Clin Oncol; 2024 May 07; 150(5):241. PubMed ID: 38713414
    [Abstract] [Full Text] [Related]

  • 24. Diagnostic value of alpha-fetoprotein, Lens culinaris agglutinin-reactive alpha-fetoprotein, and des-gamma-carboxyprothrombin in hepatitis B virus-related hepatocellular carcinoma.
    Song T, Wang L, Su B, Zeng W, Jiang T, Zhang T, Sun G, Wu H.
    J Int Med Res; 2020 Mar 07; 48(3):300060519889270. PubMed ID: 31852373
    [Abstract] [Full Text] [Related]

  • 25. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.
    Durazo FA, Blatt LM, Corey WG, Lin JH, Han S, Saab S, Busuttil RW, Tong MJ.
    J Gastroenterol Hepatol; 2008 Oct 07; 23(10):1541-8. PubMed ID: 18422961
    [Abstract] [Full Text] [Related]

  • 26. Clinical Significance of Preoperative Hepatocellular Carcinoma With High Lens culinaris Agglutinin-reactive Fraction of Alpha-Fetoprotein, But Low Alpha-Fetoprotein.
    Yamao T, Yamashita YI, Imai K, Umezaki N, Tsukamoto M, Kitano Y, Arima K, Miyata T, Nakagawa S, Okabe H, Hayashi H, Chikamoto A, Ishiko T, Baba H.
    Anticancer Res; 2019 Feb 07; 39(2):883-889. PubMed ID: 30711971
    [Abstract] [Full Text] [Related]

  • 27. A Phase 3 Biomarker Validation of GALAD for the Detection of Hepatocellular Carcinoma in Cirrhosis.
    Marsh TL, Parikh ND, Roberts LR, Schwartz ME, Nguyen MH, Befeler A, Page-Lester S, Tayob N, Srivastava S, Rinaudo JA, Singal AG, Reddy KR, Marrero JA.
    Gastroenterology; 2024 Sep 16. PubMed ID: 39293548
    [Abstract] [Full Text] [Related]

  • 28. Validation and optimization of AFP-based biomarker panels for early HCC detection in Latin America and Europe.
    Beudeker BJB, Fu S, Balderramo D, Mattos AZ, Carrera E, Diaz J, Prieto J, Banales J, Vogel A, Arrese M, Oliveira J, Groothuismink ZMA, van Oord G, Hansen BE, de Man RA, Debes JD, Boonstra A.
    Hepatol Commun; 2023 Oct 01; 7(10):. PubMed ID: 37708457
    [Abstract] [Full Text] [Related]

  • 29. Sequential fluctuation pattern of serum des-gamma-carboxy prothrombin levels detected by high-sensitive electrochemiluminescence system as an early predictive marker for hepatocellular carcinoma in patients with cirrhosis.
    Shimizu A, Shiraki K, Ito T, Sugimoto K, Sakai T, Ohmori S, Murata K, Takase K, Tameda Y, Nakano T.
    Int J Mol Med; 2002 Mar 01; 9(3):245-50. PubMed ID: 11836630
    [Abstract] [Full Text] [Related]

  • 30. Longitudinal Assessment of Three Serum Biomarkers to Detect Very Early-Stage Hepatocellular Carcinoma.
    Choi J, Kim GA, Han S, Lee W, Chun S, Lim YS.
    Hepatology; 2019 May 01; 69(5):1983-1994. PubMed ID: 30153338
    [Abstract] [Full Text] [Related]

  • 31. Utility of serological tumor biomarkers for surveillance of hepatocellular carcinoma in patients undergoing dialysis.
    Toyoda H, Kikuchi K, Tsuruta Y, Hiraoka A, Tsuji K, Tanaka J.
    Nephrol Dial Transplant; 2021 May 27; 36(6):1097-1103. PubMed ID: 33009910
    [Abstract] [Full Text] [Related]

  • 32. Refinement and validation of a comprehensive clinical diagnostic model (GAMAD) based on gender, age, multitarget circulating tumour DNA methylation signature and commonly used serological biomarkers for early detection of hepatocellular carcinoma: a multicentre, prospective observational study protocol.
    Yang T, Wang N, Wang F, Liu H, Shen F, Lv G.
    BMJ Open; 2023 Sep 18; 13(9):e076467. PubMed ID: 37723113
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Updating the Clinical Application of Blood Biomarkers and Their Algorithms in the Diagnosis and Surveillance of Hepatocellular Carcinoma: A Critical Review.
    Shahini E, Pasculli G, Solimando AG, Tiribelli C, Cozzolongo R, Giannelli G.
    Int J Mol Sci; 2023 Feb 21; 24(5):. PubMed ID: 36901717
    [Abstract] [Full Text] [Related]

  • 35. AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC.
    Yamamoto K, Imamura H, Matsuyama Y, Kume Y, Ikeda H, Norman GL, Shums Z, Aoki T, Hasegawa K, Beck Y, Sugawara Y, Kokudo N.
    J Gastroenterol; 2010 Dec 21; 45(12):1272-82. PubMed ID: 20625772
    [Abstract] [Full Text] [Related]

  • 36. Des-γ carboxyprothrombin may not be a good biomarker for hepatocellular carcinoma in those chronically infected with hepatitis B virus with basal core promoter double mutations (T^{1762}, A^{1764}), a prospective study.
    Li GJ, Chen QY, Harrison TJ, Wang XY, Hu LP, Yang QL, Li KW, Fang ZL.
    Cancer Biomark; 2017 Dec 21; 18(3):241-248. PubMed ID: 28085009
    [Abstract] [Full Text] [Related]

  • 37. Evaluation of individual and combined applications of serum biomarkers for diagnosis of hepatocellular carcinoma: a meta-analysis.
    Hu B, Tian X, Sun J, Meng X.
    Int J Mol Sci; 2013 Dec 02; 14(12):23559-80. PubMed ID: 24317431
    [Abstract] [Full Text] [Related]

  • 38. Analysis of serum α-fetoprotein-L3% and des-γ carboxyprothrombin markers in cases with misleading hepatocellular carcinoma total α-fetoprotein levels.
    Hadziyannis E, Sialevris K, Georgiou A, Koskinas J.
    Oncol Rep; 2013 Feb 02; 29(2):835-9. PubMed ID: 23174906
    [Abstract] [Full Text] [Related]

  • 39. Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C.
    Sterling RK, Wright EC, Morgan TR, Seeff LB, Hoefs JC, Di Bisceglie AM, Dienstag JL, Lok AS.
    Am J Gastroenterol; 2012 Jan 02; 107(1):64-74. PubMed ID: 21931376
    [Abstract] [Full Text] [Related]

  • 40. GALAD Score for the Diagnosis of Hepatocellular Carcinoma in Sub-Saharan Africa: A Validation Study in Ghanaian Patients.
    Nartey YA, Yang JD, Zemla TJ, Ayawin J, Asibey SO, El-Kassas M, Bampoh SA, Duah A, Agyei-Nkansah A, Awuku YA, Afihene MY, Yamada H, Yin J, Plymoth A, Roberts LR.
    Cancer Res Commun; 2024 Oct 01; 4(10):2653-2659. PubMed ID: 39324700
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.